Int J Thyroidol.  2024 Nov;17(2):259-265. 10.11106/ijt.2024.17.2.259.

Updates in the 2024 Korean Thyroid Association Clinical Practice Guidelines for Differentiated Thyroid Cancer: from Diagnosis to Initial Treatment

• Lee EK

• KMID: 2561605
• DOI: http://doi.org/10.11106/ijt.2024.17.2.259

Abstract

The 2024 Korean Thyroid Association (KTA) Clinical Practice Guidelines for Differentiated Thyroid Cancer (DTC) introduce updated recommendations based on recent advancements and clinical evidence. These guidelines encompass a broad spectrum of DTC cases, from localized thyroid cancer to advanced, treatment-resistant cases, covering both diagnostic and therapeutic approaches. Given the extensive content, careful organization was essential to effectively communicate these updates to KTA members. This article reviews the key changes in the 2024 guidelines, with a focus on revised diagnostic criteria, risk stratification, and initial treatment protocols for DTC. Updates include improved approaches to risk assessment, refinements in surgical intervention guidelines. Additionally, the new guidelines emphasize personalized management strategies that account for individual patient risk profiles and molecular characteristics. These updates aim to enhance diagnostic accuracy, optimize treatment outcomes, and minimize overtreatment for low-risk patients, aligning Korean practices with global standards.

Keyword

Guideline; Thyroid cancer; Korean; Diagnosis

Figure

• 

  Fig. 1 갑상선분화암의 초기 치료 및 추적 모식도.

• 

  Fig. 2 (Fig. I.2.1.A). Bethesda 범주에 따른 갑상선결절의 치료 또는 추적검사. K-TIRADS: Korean Thyroid Imaging Reporting and Data System

• 

  Fig. 3 (Fig. I.6.4.A). 방사성요오드 투여 전 준비 및 투여 일정 예시.

Reference

References

1. Chen DW, Lang BHH, McLeod DSA, Newbold K, Haymart MR. 2023; Thyroid cancer. Lancet. 401(10387):1531–44. DOI: 10.1016/S0140-6736(23)00020-X. PMID: 37023783.

2. Miranda-Filho A, Lortet-Tieulent J, Bray F, Cao B, Franceschi S, Vaccarella S, et al. 2021; Thyroid cancer incidence trends by histology in 25 countries: a population-based study. Lancet Diabetes Endocrinol. 9(4):225–34. DOI: 10.1016/S2213-8587(21)00027-9. PMID: 33662333.

3. Park EH, Jung KW, Park NJ, Kang MJ, Yun EH, Kim HJ, et al. 2024; Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2021. Cancer Res Treat. 56(2):357–71. DOI: 10.4143/crt.2024.253. PMID: 38487832. PMCID: PMC11016640.

4. Kim WB, Kim TY, Kwon HS, Moon WJ, Lee JB, Choi YS, et al. 2007; Management guidelines for patients with thyroid nodules and thyroid cancer. J Korean Endocr Soc. 22(3):157–87. DOI: 10.3803/jkes.2007.22.3.157.

5. Yi KH, Park YJ, Koong SS, Kim JH, Na DG, Ryu JS, et al. 2010; Revised Korean Thyroid Association management guidelines for patients with thyroid nodules and thyroid cancer. Endocrinol Metab. 25(4):270–97. DOI: 10.3803/EnM.2010.25.4.270.

6. Yi KH, Lee EK, Kang HC, Kim SW, Kim IJ, Park SY, et al. 2016; 2016 Revised Korean Thyroid Association management guidelines for patients with thyroid nodules and thyroid cancer. Int J Thyroidol. 9(2):59–126. DOI: 10.11106/ijt.2016.9.2.59.

7. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2016; 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 26(1):1–133. DOI: 10.1089/thy.2015.0020. PMID: 26462967. PMCID: PMC4739132.

8. Park YJ, Lee EK, Song YS, Koo BS, Kwon H, Kim K, et al. 2024; Korean Thyroid Association guidelines on the management of differentiated thyroid cancers; overview and summary 2024. Int J Thyroidol. 17(1):1–20. DOI: 10.11106/ijt.2024.17.1.1.

9. Park YJ, Lee EK, Song YS, Kang SH, Koo BS, Kim SW, et al. 2024; Korean Thyroid Association management guidelines for patients with thyroid nodules 2024. Int J Thyroidol. 17(1):208–44. DOI: 10.11106/ijt.2024.17.1.208.

10. Lee JY, Jo K, Kang HC, Kim SW, Park YJ, Bang JI, et al. 2024; Korean Thyroid Association guidelines on the management of differentiated thyroid cancers; Part I. Initial management of differentiated thyroid cancers - Chapter 1. Preoperative imaging and diagnostic evaluation in thyroid cancer 2024. Int J Thyroidol. 17(1):21–9. DOI: 10.11106/ijt.2024.17.1.21.

11. Ali SZ, Baloch ZW, Cochand-Priollet B, Schmitt FC, Vielh P, VanderLaan PA. 2023; The 2023 Bethesda system for reporting thyroid cytopathology. J Am Soc Cytopathol. 12(5):319–25. DOI: 10.1016/j.jasc.2023.05.005. PMID: 37438235.

12. Cho YY, Ahn SH, Lee EK, Park YJ, Choi D, Kim BY, et al. 2024; Malignancy risk of follicular neoplasm (Bethesda IV) with variable cutoffs of tumor size: a systemic review and meta-analysis. J Clin Endocrinol Metab. 109(5):1383–92. DOI: 10.1210/clinem/dgad684. PMID: 38113188.

13. Cho YY, Lee CR, Kang HC, Koo BS, Kwon H, Kim SW, et al. 2024; Korean Thyroid Association guidelines on the management of differentiated thyroid cancers; Part I. Initial management of differentiated thyroid cancers - Chapter 2. Surgical management of thyroid cancer 2024. Int J Thyroidol. 17(1):30–52. DOI: 10.11106/ijt.2024.17.1.30.

14. Ryu CH, Kang HC, Koo BS, Kim SW, Na DG, Park YJ, et al. 2024; Korean Thyroid Association guidelines on the management of differentiated thyroid cancers; Part I. Initial management of differentiated thyroid cancers - Chapter 3. Perioperative assessment of surgical complications 2024. Int J Thyroidol. 17(1):53–60. DOI: 10.11106/ijt.2024.17.1.53.

15. Shin SJ, Na HY, Kang HC, Kim SW, Na DG, Park YJ, et al. 2024; Korean Thyroid Association guidelines on the management of differentiated thyroid cancers; Part I. Initial management of differentiated thyroid cancers - Chapter 4. Pathological diagnosis and staging after thyroidectomy 2024. Int J Thyroidol. 17(1):61–7. DOI: 10.11106/ijt.2024.17.1.61.

16. Lee EK, Song YS, Kang HC, Kim SW, Na DG, Moon SJ, et al. 2024; Korean Thyroid Association guidelines on the management of differentiated thyroid cancers; Part I. Initial management of differentiated thyroid cancers - Chapter 5. Evaluation of recurrence risk postoperatively and initial risk stratification in differentiated thyroid cancer 2024. Int J Thyroidol. 17(1):68–96. DOI: 10.11106/ijt.2024.17.1.68.

17. Park S, Chong A, Kang HC, Kim K, Kim SW, Na DG, et al. 2024; Korean Thyroid Association guidelines on the management of differentiated thyroid cancers; Part I. Initial management of differentiated thyroid cancers - Chapter 6. Radioactive iodine treatment after thyroidectomy 2024. Int J Thyroidol. 17(1):97–110. DOI: 10.11106/ijt.2024.17.1.97.

18. Park S, Bang JI, Kim K, Seo Y, Chong A, Hong CM, et al. 2024; Comparison of recombinant human thyroid-stimulating hormone and thyroid hormone withdrawal for 131 I therapy in patients with intermediate- to high-risk thyroid cancer : a systematic review and meta-analysis. Clin Nucl Med. 49(3):e96–e104. DOI: 10.1097/RLU.0000000000005022. PMID: 38271262.

19. Chong A, Seo Y, Bang JI, Park S, Kim K, Hong CM, et al. 2024; Clinical implications of adding SPECT/CT to radioiodine whole-body scan in patients with differentiated thyroid cancer: a systematic review and meta-analysis. Clin Nucl Med. 49(3):215–25. DOI: 10.1097/RLU.0000000000004953. PMID: 38048517.